A world-first clinical trial has found that a simple daily nasal spray can significantly reduce the risk of COVID-19 in cancer patients, offering a potential new tool to protect vulnerable people from the virus.
A new diagnostic method would confirm sepsis infections earlier, cutting critical hours in the “race against time” to save patients’ lives.
Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously deadly and difficult to treat.
Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.
When genetic testing reveals a rare DNA mutation, doctors and patients are frequently left in the dark about what it actually means. Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful new way to determine whether a patient with a mutation is likely to actually develop disease, a concept known in genetics as penetrance.
Current ALS diagnosis relies on neurological evaluations and the presence of symptoms; at present, there is no definitive diagnostic test.
VaxSeer uses machine learning to predict virus evolution and antigenicity, aiming to make vaccine selection more accurate and less reliant on guesswork.
Current ALS diagnosis relies on neurological evaluations and the presence of symptoms, with no definitive diagnostic test currently available.
In a recent study, researchers introduced an origami-inspired “facet-driven folding” strategy using polygonal hydrogel pores to deliver highly controlled, programmable actuation, opening new possibilities for selective drug delivery and information encryption.
A novel, multi-analyte test developed by researchers at the Johns Hopkins Kimmel Cancer Center, its Ludwig Center and the Johns Hopkins Department of Neurosurgery can accurately identify brain cancers using small samples of cerebrospinal fluid (CSF), offering a promising new tool to guide clinical decision-making.